Fluticasone furoate / Umeclidinium / Vilanterol: brand names and study card
Fluticasone furoate / Umeclidinium / Vilanterol — ICS + LAMA + LABA combination inhaler. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Upper respiratory tract infection; Pneumonia; Oral candidiasis; Headache; Back pain
Warnings
Not for relief of acute bronchospasm; Increased pneumonia risk in COPD; LABA without an inhaled corticosteroid increases asthma-related death risk. Large fixed ICS/LABA trials did not show a significant increase in serious asthma events versus ICS alone, but did not rule out all risk
Interactions
Strong CYP3A4 inhibitors; MAOIs and tricyclic antidepressants; Beta-blockers
Label date: 20230602 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
On both cards: Used for — COPD maintenance · Common side effects — Upper respiratory tract infection; Oral candidiasis; Headache; Back pain · Warnings — Not for relief of acute bronchospasm; Increased pneumonia risk in COPD · Interactions — Strong CYP3A4 inhibitors; MAOIs and tricyclic antidepressants; Beta-blockers
Only on the Fluticasone furoate / Vilanterol card: Used for — Asthma maintenance from age 5, for the cited ELLIPTA inhalation powder · Common side effects — Nasopharyngitis · Warnings — LABA without an inhaled corticosteroid increases asthma-related death risk. Large fixed ICS/LABA trials did not show significantly increased serious asthma events versus ICS alone, but did not rule out all risk
On both cards: Common side effects — Upper respiratory tract infection; Oral candidiasis; Headache · Interactions — Strong CYP3A4 inhibitors; Beta-blockers
Only on the Fluticasone Propionate / Salmeterol card: Used for — Asthma maintenance from age 4 when an inhaled corticosteroid alone is inadequate or combined ICS/LABA therapy is warranted; COPD maintenance and exacerbation reduction with the specifically indicated DISKUS strength · Common side effects — Pharyngitis; Dysphonia · Warnings — Not for acute bronchospasm; Pneumonia in COPD; Adrenal suppression / reduced bone density · Interactions — MAOIs / tricyclic antidepressants
On both cards: Common side effects — Upper respiratory tract infection; Oral candidiasis; Headache · Interactions — Strong CYP3A4 inhibitors; Beta-blockers
Only on the Budesonide / Formoterol card: Used for — Asthma maintenance from age 6 when an inhaled corticosteroid alone is inadequate or combined ICS/LABA therapy is warranted; COPD maintenance and exacerbation reduction with the specifically indicated 160/4.5 inhalation-aerosol strength · Common side effects — Nasopharyngitis; Sinusitis · Warnings — Not for acute bronchospasm; Pneumonia in COPD; Adrenal suppression / immunosuppression · Interactions — MAOIs / tricyclic antidepressants
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera